secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001178913-22-001896
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab Q1 net loss $5.1M; cash $57.5M; advancing CM-101 in PSC and SSc
------------------------------------------------------------------------

- Net loss of $5.1M ($0.02 per share) vs $1.7M in Q1 2021; R&D expenses $2.7M, G&A $2.6M (incl $0.9M stock comp).
- Cash and equivalents $57.5M at March 31, 2022, down from $61.2M at Dec 31, 2021.
- Completed enrollment in Phase 2 liver fibrosis study; interim PSC readout expected late 2022; SSc Phase 2 launch planned by year-end.
- Appointed Jack Lawler as VP of Global Clinical Development Operations.
- Presented CCL24 data at SSc congress; findings support CM-101's role in fibrosis and endothelial damage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/0001178913-22-001896-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891322001896/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-001896

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer